Home/Filings/4/0001104659-19-015612
4//SEC Filing

Andrews Kurt J. 4

Accession 0001104659-19-015612

CIK 0000722830other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 4:35 PM ET

Size

8.0 KB

Accession

0001104659-19-015612

Insider Transaction Report

Form 4
Period: 2019-03-14
Andrews Kurt J.
CHIEF HUMAN RESOURCES OFFICER
Transactions
  • Award

    Stock Option (right to buy)

    2019-03-14+28,51028,510 total
    Exercise: $17.94Exp: 2026-03-14Common Stock, par value $0.01 per share (28,510 underlying)
  • Award

    Stock Option (right to buy)

    2019-03-14+14,26014,260 total
    Exercise: $17.94Exp: 2026-03-14Common Stock, par value $0.01 per share (14,260 underlying)
Footnotes (2)
  • [F1]The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
  • [F2]The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.

Documents

1 file

Issuer

IMMUNOMEDICS INC

CIK 0000722830

Entity typeother

Related Parties

1
  • filerCIK 0001636133

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 4:35 PM ET
Size
8.0 KB